Pramipexole-5HT3 Antagonist Combination for GI-Limited Depression Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for depression, particularly major depressive disorder (MDD), are often ineffective and associated with significant adverse effects, limiting the therapeutic window of pramipexole, a dopamine agonist used for Parkinson's disease, despite its potential antidepressant efficacy.
Innovation Solution
Combining pramipexole with a 5HT3-antagonist, such as ondansetron, to mitigate gastrointestinal side effects and allow for higher, safer doses of pramipexole, thereby enhancing its antidepressant efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher doses of pramipexole are used to treat depression, then antidepressant efficacy is improved, but gastrointestinal side effects worsen
Solution Approach 1:
A 5HT3-antagonist is introduced as a mediator substance that blocks the gastrointestinal side effects of pramipexole without interfering with its antidepressant mechanism. The 5HT3-antagonist selectively antagonizes serotonin receptors in the GI tract, allowing higher pramipexole doses to be administered tolerably for depression treatment.
Solution Approach 2:
The patent creates a composite pharmaceutical formulation combining pramipexole and 5HT3-antagonist in a fixed-dose combination. This composite approach allows the two substances to work synergistically, with pramipexole providing antidepressant efficacy and the 5HT3-antagonist mitigating gastrointestinal adverse effects.
2Reliability
If maximum recommended dose of pramipexole is used for Parkinson's disease, then motor symptoms are controlled, but therapeutic window for depression treatment is limited
Solution Approach 1:
The fixed-dose combination formulation serves multiple functions: it maintains pramipexole's effectiveness for Parkinson's disease motor symptoms while simultaneously expanding the therapeutic window for depression treatment. The 5HT3-antagonist component enables the same formulation to be used across different therapeutic indications with reduced side effects.
Solution Approach 2:
The combination formulation changes the safety parameter profile of pramipexole by reducing gastrointestinal toxicity through 5HT3-antagonist co-administration. This parameter change allows dose escalation beyond the maximum recommended for Parkinson's disease into a range that provides superior antidepressant efficacy while maintaining acceptable tolerability.
3Reliability
If current antidepressant treatments are used, then depression is treated, but adverse effects are significant
Solution Approach 1:
The patent converts the harmful gastrointestinal effects of pramipexole into a beneficial opportunity by using the 5HT3-antagonist to block these side effects. What would normally be a limiting adverse effect becomes a manageable parameter, allowing the exploitation of pramipexole's antidepressant potential at higher doses with improved safety.
Data Source
AI summary
The present invention describes the combination of a 5HT3-antagonist with pramipexole to reduce or eliminate the adverse effects associated with the use of pramipexole and to enable the use of high doses of pramipexole, useful for treating depressive disorders such as major depressive disorder.